Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC)
Publication
, Journal Article
Harrison, MR; Hahn, N; Pili, R; Oh, WK; Kim, K; Wilding, G; Sweeney, CJ; Sidor, C; Arnott, J; Liu, G
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
5173 / 5173
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, M. R., Hahn, N., Pili, R., Oh, W. K., Kim, K., Wilding, G., … Liu, G. (2008). Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology, 26(15_suppl), 5173–5173. https://doi.org/10.1200/jco.2008.26.15_suppl.5173
Harrison, M. R., N. Hahn, R. Pili, W. K. Oh, K. Kim, G. Wilding, C. J. Sweeney, C. Sidor, J. Arnott, and G. Liu. “Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5173–5173. https://doi.org/10.1200/jco.2008.26.15_suppl.5173.
Harrison MR, Hahn N, Pili R, Oh WK, Kim K, Wilding G, et al. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):5173–5173.
Harrison, M. R., et al. “Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, May 2008, pp. 5173–5173. Manual, doi:10.1200/jco.2008.26.15_suppl.5173.
Harrison MR, Hahn N, Pili R, Oh WK, Kim K, Wilding G, Sweeney CJ, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):5173–5173.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
5173 / 5173
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences